Navigation Links
Aerolef in Medical Technology

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF(TM) in o...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data f...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
Aerolef in Biological Technology

YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL

... - Dr. Ali Raza To Lead Further Development Of aerolef As President Of aerolef Division - MISSISSAUGA, ON, June 19 /PRNewswire-...of the Phase II clinical development of AeroLEF. aerolef is being developed as a novel and effective approa...
Other Tags
(Date:9/19/2014)... Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, ... in the Journal of the National Cancer Institute ... melanoma. , "For the first time, we have established ... play a part in the risk of developing melanoma," ... School of Medicine at the University of Leeds (UK). ...
(Date:9/19/2014)... 2014 According to a report from ... blood-thinner Xarelto, named as defendants in several lawsuits filed ... moved the court to dismiss those suits because the ... connection with Philadelphia.* The cases include, for instance, Fontan ... Pa. Comm. Pls., Philadelphia Cty.), which was brought by ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... News) -- The U.S. Food and Drug Administration approved a ... part of a class of once-a-week injectable drugs that help ... "Trulicity is a new treatment option, which can ... control blood sugar levels in the overall management of type ... Office of Drug Evaluation II, said in an agency news ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
(Date:9/18/2014)... colleagues have built the first smartphone app that ... behavioral trends. In other words, your smartphone knows ... don,t -- and how that affects you. , ... depression and loneliness to their academic performance, also ... for example, to monitor mental health, trigger intervention ...
(Date:9/18/2014)... so you might expect that most would have an ... dogs are distinctly more pessimistic than others, research from ... is exciting because it measures positive and negative emotional ... and dog owners an insight into the outlook of ... from the Faculty of Veterinary Science. Her PhD research ...
(Date:9/18/2014)... The global cycles of carbon and nitrogen comprise ... human and environmental systems have caused imbalances and ... greenhouse gases (GHGs). Increased GHGs result in climate ... terrestrial ecosystems, oceans and the atmosphere. Understanding these ... exciting branch of environmental science during the past ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Dogs can be pessimists too 2Dogs can be pessimists too 3Greenhouse gas research enters a new era 2
Other Contents